Cardiovascular safety of febuxostat - Authors' reply
- PMID: 34509228
- DOI: 10.1016/S0140-6736(21)01383-0
Cardiovascular safety of febuxostat - Authors' reply
Conflict of interest statement
TMM reports grants from Novartis, Pfizer, GlaxoSmithKline, Amgen, and Menarini, unrelated to this Correspondence, and consultancy or speaker fees from Novartis, Takeda, Servier, Shire, Astellus, Menarini, and AstraZeneca. GN, MR, and IF report grants from Menarini via the University of Dundee, unrelated to this Correspondence. ISM reports research grants from Novartis, the National Institute for Health Research Health Technology Assessment programme, Amgen, Research Triangle Institute, Tenovus Scotland, George Clinical, European Medicines Agency, Sanofi, Health Data Research UK, Innovative Medicines Initiative, and Menarini, and personal income from AstraZeneca, unrelated to this Correspondence.
Comment on
-
Cardiovascular safety of febuxostat.Lancet. 2021 Sep 11;398(10304):954-955. doi: 10.1016/S0140-6736(21)01385-4. Lancet. 2021. PMID: 34509227 No abstract available.
-
Cardiovascular safety of febuxostat.Lancet. 2021 Sep 11;398(10304):955. doi: 10.1016/S0140-6736(21)01386-6. Lancet. 2021. PMID: 34509229 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical